Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15695MR)

This product GTTS-WQ15695MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Macular edema following Central Retinal Vein Occlusion (CRVO), Diabetic retinopathy research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15695MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3185MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ2946MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ANB-011
GTTS-WQ3502MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ12387MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA NEOD-001
GTTS-WQ3686MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ8668MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ12514MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NOE-102
GTTS-WQ725MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA A-623
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW